Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

The EURING Data Bank – a critical tool for continental-scale studies of marked birds

The European Union for Bird Ringing (EURING) coordinates bird ringing at a continental scale and operates the EURING Data Bank (EDB) to facilitate large-scale analyses of movements and demography. The EDB contains over 10 million individual encounter records which are summarised on a publicly available website, the EDB index. EURING welcomes applications to analyse these data. Ring-recovery data from the EDB contribute to research on many ecological issues, particularly migration and movements, hunting, mortality causes, disease transmission, population dynamics and dispersal. Recent developments will facilitate the incorporation of comprehensive sets of first-encounter records and local recaptures which are essential for robust quantitative studies of population dynamics and movements. Furthermore, the recent inclusion of fields for moult, measurements and weights within the EURING code will facilitate novel research at a European scale. We expect increasing use of the EDB for quantitative studies of avian demography and movements with high applied value. Wherever possible, this research should also incorporate complementary ecological information. EURING’s immediate priority is the production of a European Migration Atlas that would provide an up-to-date synthesis of the movements of European bird populations, with many direct implications for their conservation.publishe